Pathfinder Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Market growth in image-guided surgery will come, in part, from new technologies that can guide surgeons in soft tissue. Pathfinder Therapeutics Inc. thinks its IGS platform, built on 15 years of academic R&D by pioneers in IGS, fits the bill. The first application is for the large, unmet need in treating liver cancer. Currently, just 20% of patients are eligible for open liver surgery, the current gold standard treatment.